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While the induction of a neutralizing antibody response against HIV remains a daunting goal, data from both 
natural infection and vaccine-induced immune responses suggest that it may be possible to induce antibodies 
with enhanced Fc effector activity and improved antiviral control via vaccination. However, the specific features 
of naturally induced HIV-specific antibodies that allow for the potent recruitment of antiviral activity and the 
means by which these functions are regulated are poorly defined. Because antibody effector functions are crit-
ically dependent on antibody Fc domain glycosylation, we aimed to define the natural glycoforms associated 
with robust Fc-mediated antiviral activity. We demonstrate that spontaneous control of HIV and improved 
antiviral activity are associated with a dramatic shift in the global antibody-glycosylation profile toward agalac-
tosylated glycoforms. HIV-specific antibodies exhibited an even greater frequency of agalactosylated, afucosy-
lated, and asialylated glycans. These glycoforms were associated with enhanced Fc-mediated reduction of viral 
replication and enhanced Fc receptor binding and were consistent with transcriptional profiling of glycosyl-
transferases in peripheral B cells. These data suggest that B cell programs tune antibody glycosylation actively 
in an antigen-specific manner, potentially contributing to antiviral control during HIV infection.
Introduction
Despite the recent identification of novel monoclonal antibodies 
with exceptionally broad neutralization potencies, such neutralizing 
responses have been remarkably difficult to induce via vaccination. 
However, results from the RV144 vaccine trial, in which protection 
from infection was observed in 31% of vaccinees in the absence of neu-
tralizing antibody responses and cytotoxic T cell responses, have reen-
ergized interest in nonneutralizing antibody responses against HIV 
infection (1, 2). Beyond neutralization, antibodies are able to medi-
ate a variety of additional effector functions through their capacity 
to recruit the innate immune system via Fc receptors (FcRs). More-
over, these antibodies are readily induced early in HIV infection, are 
enriched in long-term nonprogressors, and have been shown to pro-
vide protection in some models (3–7). However, the specific antibody 
characteristics that are associated with enhanced innate immune 
activity have yet to be defined. Based on strong genetic and clinical 
data from antibody therapeutics, as well as passive transfer and chal-
lenge studies in HIV, recruitment of innate immunity is a key factor 
in antibody activity in vivo, and, therefore, understanding these char-
acteristics is likely to be important for vaccine development efforts.
The ability of antibodies to recruit innate immune effector cells 
is tunable, both in terms of the spectrum of innate immune cells 
recruited and the responses induced, ranging from proinflamma-
tory to antiinflammatory depending on the specific FcRs engaged 
(8). Several antibody features determine innate immune recruiting 
capacity, including antibody titer, affinity, epitope specificity, and 
polyclonality, each playing a significant role in effector function 
by impacting the geometry and valency of the immune complexes 
formed. Because many of the innate immune receptors for anti-
bodies are of low affinity, avid interactions are required to create 
multivalent immune complexes to cluster receptors and drive cel-
lular activation (9). Furthermore, because these innate receptors 
are expressed on cellular surfaces, spatial arrangement of both 
antibody and receptor can have an impact on recognition and 
induction of effector functions (10, 11).
Beyond these variable domain features that modulate the 
potency of the humoral immune response, antibodies provide 
instructions to the innate immune system on how to clear com-
plexed antigens via their Fc domain, providing an additional 
level of regulated control over antibody activity. Despite its 
nomenclature, the constant domain (Fc) of an antibody pos-
sesses a large number of possible states with regard to antibody 
potency. The 4 subclasses of IgG (IgG1, IgG2, IgG3, IgG4) vary 
somewhat in amino acid sequence but dramatically in their abil-
ity to bind innate immune receptors (12). Furthermore, within 
a given subclass, the inflammatory properties are more finely 
regulated by the specific glycan incorporated on Asn297 of the 
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heavy chain, which may be 1 of >30 sugar structures that greatly 
influences the affinity between IgG and FcRs or complement 
proteins (13). Glycosylation of the Fc domain critically modu-
lates the ability of an antibody to interact with FcRs — permit-
ting bidirectional control and tuning of an antibody’s inflam-
matory or antiinflammatory activity and selective engagement 
of particular innate effector cell activities.
Global antibody glycosylation is altered in numerous disease 
states, and these alterations can be highly functionally relevant, as 
changes in fucose and sialic acid content can lead to a thousand-
fold improvement in the antibody-dependent cellular cytotoxicity 
(ADCC) activity or, conversely, grant antibodies antiinflammatory 
properties (14, 15). While a complete structure/function map of 
antibody glycans is lacking, the presence or absence of 3 specific 
sugar residues on this N-linked biantennary glycan dramatically 
modulates antibody interactions with FcR. Fucosylation of the 
mannose core impacts recognition by the activating FCGR3A (14); 
sialylation of terminal galactose groups is associated with antiin-
flammatory activity and reduced FcγR binding (15); and decreased 
galactosylation has been implicated in altered interactions with 
complement proteins (16). Previous work has shown that chronic 
progressive HIV infection is associated with an enrichment of anti-
bodies with agalactosylated (G0) glycans (17), also associated with 
autoimmune relapse or flares (18).
The N-linked glycans found at Asn297 can be divided into 3 
major classes: (a) G0 structures, which are agalactosylated and 
associated with inflammation; (b) G1 structures, which are singly 
galactosylated species abundant in healthy individuals; and (c) G2 
structures, which possess 2 galactose groups and are associated 
with antiinflammatory activity, as they have an increased potential 
to be sialylated.
While neutralizing antibody responses emerge in only a frac-
tion of HIV-infected individuals with progressive disease, innate 
immune recruiting antibodies, such as those able to elicit ADCC 
or, more broadly, antibody-dependent cellular viral inhibition 
(ADCVI) emerge in the majority of individuals able to spontane-
ously control HIV infection (3, 4). These data point to a potential 
role of these humoral immune responses in the control of infec-
tion. However, little is known about the biophysical properties of 
naturally produced antibodies that are able to potently recruit the 
antiviral activity of the innate immune system, and less is known 
about the degree of antibody glyco-variation in the context of 
infection, in which naturally induced glycovariants contribute 
most profoundly to antiviral control, or whether glyco- variation 
is actively harnessed by the immune system naturally to gain 
more effective control of infection. Here we report that while HIV 
infection is marked by a bulk antibody shift toward glycans asso-
ciated with inflammation, spontaneous control of HIV is asso-
ciated with the production of antigen-specific antibodies with 
unique glycoforms superbly tuned to recruit the antiviral activity 
of the innate immune system. These data suggest that unique 
antigen-specific B cell programs can result in skewed antibody 
glycosylation, which may contribute to potent antiviral control 
during progressive HIV infection.
Results
Antiviral effector activity of antibodies from HIV-infected subjects. To 
begin to define the specific humoral properties associated with 
the antiviral activity of innate immune recruiting antibodies, anti-
bodies from patients with differential disease progression were 
isolated from plasma and used in an ADCVI assay (19, 20), which 
measures both cytolytic and noncytolytic mechanisms of antiviral 
activity. In this long-term assay, neutralizing activity against this 
tier 2 virus was rare in all subject groups (Figure 1A). However, 
antibodies from elite controllers and chronic patients on therapy 
elicited the antiviral activity of NK cells to inhibit viral replication 
more potently than antibodies from untreated chronic progres-
sors (Figure 1A), implying that low-level viral replication may be 
associated with the induction of more potent innate immune 
recruiting antibody responses. Additionally, antibodies from viral 
controllers induced more robust NK cell responses, with a more 
multifunctional profile and greater extent of degranulation (Fig-
ure 1B), suggesting that even among subjects with potent inhi-
bition of viral outgrowth, qualitative differences in the innate 
immune recruiting capacity of humoral immune responses exist.
In order to account for the mechanism of this differential activ-
ity, each of the 3 antibody features known to modulate innate 
immune recruiting potential was investigated. No differences were 
observed in antibody titer or IgG subclass distribution in either 
bulk or HIV-specific antibodies among the different patient pop-
ulations (data not shown), consistent with previous reports (21), 
suggesting that these features could not account for the differ-
ences observed in ADCVI activity. In contrast, enzymatic removal 
of the glycan from the antibody heavy chain resulted in profound 
loss of ADCVI activity (Figure 1C).
Global antibody glycosylation is altered by HIV infection. Thus, to 
determine whether specific changes in the distribution of anti-
body glycan structures could be associated with differences in the 
magnitude of ADCVI activity observed among patient groups, 
the distribution of glycoforms among the different patient pop-
ulations was compared. The N-glycans were identified by nega-
tive-ion electrospray collision–induced fragmentation (ESI-CID) 
mass spectrometry, and their relative proportions were measured 
by MALDI-TOF mass spectrometry. The identified glycans were 
complex biantennary species, with and without fucose and/or a 
“bisecting” GlcNAc (attached to the 4 position of the branching 
mannose) and with 0, 1, or 2 galactose residues. The structures 
of the glycans are outlined in ref. 22 and Supplemental Fig-
ure 1 (supplemental material available online with this article; 
doi:10.1172/JCI65708DS1).
Interestingly, we observed a marked shift in the proportion of 
agalactosylated glycan species on bulk antibodies in infected sub-
jects compared with that in healthy controls (Figure 1D). This 
expansion of G0 glycans occurred at the expense of G1 and G2 
class glycans, which, as expected, were prevalent forms in the 
healthy HIV-negative controls. Surprisingly, perturbation of 
global plasma IgG glycosylation was apparent even during acute 
infection, indicating that despite the long plasma half-life of IgG, 
infection rapidly impacts the composition, and therefore activity, 
of the antibody compartment. Furthermore, although elite con-
trollers durably maintain HIV replication to undetectable levels 
and exhibit low-level systemic immune activation (23, 24), the 
shift toward agalactosylated glycans was even more pronounced 
in these individuals compared with that in both treated and 
untreated chronically infected subjects (Figure 1D), suggesting 
that unlike the T cell compartment, the B cell compartment in 
elite controllers is inflamed (25), resulting in the production of 
antibodies with altered glycan composition. However, despite 
this change, the increase in G0 could not explain the difference in 
ADCVI activity among infected subject groups.
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Because core α1-6–linked fucose has been implicated in potently 
modulating ADCC activity via altered affinity for FCGR3A, an 
activating FcγR expressed on NK and other innate cells (14, 26), 
we next sought to determine whether lack of fucose was associ-
ated with enhanced antibody effector activity and compared the 
overall levels of fucosylated and nonfucosylated antibodies among 
patient populations. While no difference was observed in the over-
all frequency of nonfucosylated glycoforms (Figure 1D), decon-
volution of the fucosylated and nonfucosylated forms of each of 
the G0, G1, and G2 glycan forms revealed some differences in the 
frequency of nonfucosylated and branched glycan species among 
subject groups (Figure 2).
HIV-specific antibodies exhibit potentiated glycan skewing. To gain 
refined insight into the glycan changes specifically associated 
with the improved innate immune recruiting activity of anti-
bodies from controllers and treated subjects observed in ADCVI 
assays, antigen-specific antibodies were affinity purified, and the 
glyco-variation on envelope-specific antibodies, likely involved in 
mediating this antiviral function, was determined. Significantly, 
the HIV-specific antibody compartment in all 3 patient groups 
showed evidence of both inflammation and increased inflamma-
tory activity, exhibiting increases in nonfucosylated, G0, and G1 
glycans, and decreases in the less activating, fucosylated G2F and 
G1F glycans (Figure 3A). Several subjects exhibited remarkable lev-
els of nonfucosylated HIV-specific antibodies, with greater than 
50% of envelope-specific antibodies lacking fucose. Additionally, 
there was a trend toward reduced sialylation of the HIV-specific 
antibodies (P = 0.09, unpaired t test; data not shown). This shift 
toward decreased fucose, galactose, and sialic acid on HIV-specific 
antibodies is consistent with a mechanism controlling glycosy-
lation on an antigen-specific basis, rather than simply via global 
inflammatory signals.
Despite their significant activity differences, only minor dif-
ferences in the total galactose or fucose content of HIV-specific 
antibodies were observed among subject groups, although aga-
lactosylated glycans were somewhat enriched in the HIV-specific 
antibodies of elite controllers (Figure 3B).
However, when comparisons were made as to differences 
observed in bulk and HIV-specific antibodies within each sub-
ject group, controllers clearly exhibited more robust glyco-varia-
tion than chronic progressors (Supplemental Figure 2). Relative 
to bulk plasma IgG, the inflammatory nonfucosylated, G0, and 
G1 glycoforms were significantly enriched only in elite control-
lers, and antiinflammatory sialylated and G1F glycoforms were 
reduced (Figure 4A), consistent with the increased ADCVI activity 
observed in this population and indicative of more robust anti-
gen-specific modulation of glycan in these subjects. Additionally, 
when HIV-specific antibody glycans were compared among sub-
Figure 1
Effector function and global antibody glycosylation profiles. (A) Antibodies from HIV-infected subjects were examined for their ability to inhibit viral 
replication via neutralization (AB) or ability to recruit NK cells as effectors (NK + AB) in an ADCVI assay. Colored bars correspond to unique glycan 
structures. (B) NK cell degranulation (dot plot) and cytokine secretion were determined in the ADCVI assay. Pie charts depict the polyfunctional 
profile of antibody-mediated NK cell recruitment, including degranulating NK cells (CD107a, 1 function), IFN-γ secretion plus degranulation 
(2 functions), or IFN-γ plus TNF-α plus degranulation (3 functions). (C) Glycan dependence of ADCVI activity. Removal of antibody glycan with 
the endoglycosidase PNGaseF did not affect neutralization (AB), but ablated viral inhibition resulting from recruitment of NK cells as effectors 
(AB+). (A–C) Individual symbols represent each subject tested, and horizontal lines represent the median for a given group of clinically related 
subjects. (D) Global plasma IgG glycosylation profiles for all glycan structures (first panel), galactose content (second panel), and fucose content 
(third panel). neg, healthy controls; acute, acutely HIV-infected subjects; untx, untreated chronic progressors; tx, treated chronic progressors; ctr, 
controllers; F, fucosylated; nonF, nonfucosylated.
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ject groups, elite controllers possessed significantly lower levels of 
G1F, G2F, and bigalactosylated glycans and higher levels of aga-
lactosylated glycoforms on HIV-specific antibodies compared with 
untreated chronic progressors (Figure 4B). Because galactosylated 
glycoforms have the potential to be sialylated, these alterations in 
galactose content may covary with sialylation. Indeed, the trend 
toward reduced sialylation observed in controllers is consistent 
with such covariance, as can be readily observed in bulk glycans 
(Supplemental Figure 3).
Last, relative to uninfected controls, bisected glycans, previously 
associated with reduced incorporation of fucose and therefore 
exhibiting higher ADCC (27), were enriched in all infected subject 
groups, and this enrichment was most profound in treated sub-
jects (Figure 2 and Figure 4B), potentially conferring an alternate 
route by which treated patients may regain some capacity to recruit 
NK cell–mediated antiviral control (Figure 1A). These data suggest 
that progressive HIV disease, marked by high-level viral replication, 
either persistently or prior to the initiation of antiretroviral ther-
apy, results in a generalized production of more bisected glycans 
on both HIV-specific and total immunoglobulins and may offer an 
alternative strategy by which treated chronic progressors explore 
glycan structures to enhance ADCVI/ADCC activity.
Antibody galactosylation is associated with antiviral activity. Enrichment 
of agalactosylated glycans was associated with increased ADCVI, 
whereas bigalactosylated glycans were associated with reduced effec-
tor function (Figure 5, A and B, respectively). As a negative control, 
neutralization activity did not correlate with any glycan structures 
(data not shown). Additionally, ADCVI activity correlated positively 
with binding to FCGR3A (Figure 5C). Despite the well-characterized 
affinity improvement of nonfucosylated glycans to FCGR3A, the 
correlation between ADCVI activity and the abundance of nonfuco-
sylated glycoforms did not reach statistical significance, indicating 
that in the context of naturally raised antibodies, galactose levels 
may play a more significant role in ADCVI activity than the presence 
or absence of fucose. Because reduced galactosylation has not been 
associated with potentiated ADCC activity in monoclonal antibod-
ies, the association observed here may reflect concomitant varia-
tions in the overall glycan structure, such as altered sialylation, as is 
implied by the reduced sialylation of HIV-specific antibodies and a 
relationship between galactose and sialic acid content (Supplemen-
tal Figure 3). However, others have shown that antibody affinity 
purification of IgG on FCGR3A resin favored G0 glycan enrichment 
by 10%, whereas both G1 and G2 glycoforms were decreased by 10% 
and 20%, respectively (28), consistent with a FCGR3A preference for 
G0 antibody glycans. Moreover, to confirm the biophysical inter-
action of agalactosylated glycans with FCGR3A, antibody samples 
from 4 subjects were enzymatically treated with a galactosidase, 
resulting in increased G0 glycan and decreased G2 content (Figure 
5, D and E). When the ability of these antibodies to bind to FCGR3A 
conjugated to a Luminex bead was assessed, the enzyme-treated 
pool exhibited significantly higher binding (Figure 5F), whereas no 
impact on FcgR1 binding was observed (data not shown), strongly 
supporting a preferential physical interaction between FCGR3A and 
agalactosylated antibodies.
Figure 2
Complete glycan prevalence data for bulk plasma IgG. Relative prevalences (%) of all observed glycoforms in HIV-negative, acute-infected, 
treated, and untreated subjects and HIV controllers. Colored underlays represent Tukey’s bars and whiskers. In box-and-whisker plots, horizontal 
bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and 90th percentiles.
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B cell glycosyltransferase expression is consistent with antibody glycan 
alterations. To probe the mechanism underlying differential gly-
cosylation among these subject groups, transcriptional profiling 
of glycosyltransferases (GTs) and glycosidases associated with 
the antibody glycan was performed. Expression of 16 GTs (Sup-
plemental Table 2) that may be involved in the biosynthesis of 
N-linked glycans was determined. When a classifier was trained 
with 5-fold cross-validation using this data set, it was able to use 
GT expression data to correctly predict whether a subject was 
infected or uninfected, averaging better than 85% accuracy. When 
applied to further distinguish among infected classes, a classi-
fier differentiated among controllers, untreated subjects, and 
HIV-negative individuals with better than 70% accuracy on average 
but poorly resolved treated subjects and assigned the majority of 
these subjects to the controller class (data not shown). Indeed, the 
similarity in GT profiles between treated subjects and controllers 
is consistent with the glycosylation data reported here. Untreated 
subjects expressed higher levels of GT transcripts associated with 
Figure 3
HIV-specific antibodies exhibit dramatically inflammatory glycosylation profiles. (A) Relative prevalence of glycans on bulk plasma and anti-
gen-specific antibodies. Statistical analysis was performed using Wilcox matched-pairs signed-rank test. NF, nonfucosylated. **P < 0.005; 
***P < 0.0005. (B) Glycosylation profiles of HIV-specific antibodies for all glycan structures (first panel), galactose content (second panel), and 
fucose content (third panel).
Figure 4
Comparative glycan profiles of bulk plasma and HIV-specific antibodies in each HIV-positive subject class. (A) Significant differences observed 
between bulk and HIV-specific antibodies within each subject group. (B) Significant differences observed in HIV-specific antibodies among subject 
groups. In box-and-whisker plots, horizontal bars indicate the medians, boxes indicate 25th to 75th percentiles, and whiskers indicate 10th and 
90th percentiles. Dots outside of box plots represent outliers. *P < 0.05.
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the constitutive components of the glycan, including MGAT1, 
MGAT2, and ALG2 (Figure 6A), which may reflect the hypergam-
maglobulinemia present in this population. Expression of the 
fucosyltransferase responsible for core fucosylation, FUT8, was 
decreased in controllers and treated progressors relative to that in 
untreated progressors (Figure 6B), while the fucosidase, FUCA2, 
was enriched in controllers and untreated subjects (Figure 6B). 
While the biological relevance of FUCA2 expression in B cells is 
unproven, these expression patterns are nonetheless consistent 
with the observation of decreased fucosylation in HIV-infected 
subjects. Expression changes in galactose transferases were also 
observed (Figure 6C), with HIV-infected subjects exhibiting sig-
nificantly lower expression of one or both galactose transferases 
studied. Overall, the alterations in GT expression were consistent 
with the hypergammaglobulinemia (Figure 6A), decreased fuco-
sylation (Figure 6B), and decreased galactosylation (Figure 6C) 
observed in the antibodies of infected subjects. Further study of 
GT expression in HIV-specific B cells is likely to yield additional 
insight into B cell modulation of antibody activity.
Discussion
The complexity of antibody functions mediated through FcRs belies 
the ability of the humoral immune system to tightly regulate recruit-
ment of innate effector cells to rapidly clear the antigens to which 
they are bound. While only a subset of individuals with progressive 
HIV infection are able to mount neutralizing antibody activity, indi-
viduals that spontaneously control HIV infection generally produce 
antibodies with a robust capacity to recruit the antiviral activity of 
the innate immune system, suggesting that innate immune recruit-
ing antibodies, rather than neutralizing antibody responses, may 
be vital in antiviral control. Therefore, efforts to better understand 
the characteristics of naturally induced innate immune recruiting 
antibodies may provide novel information to help improve the func-
tional quality of vaccine-induced antibodies. Significantly, antibod-
ies from HIV-infected subjects vary dramatically in their ability to 
recruit the cytotoxic functions of NK cells, and these differences 
could not be attributed to either titer or IgG subclass. Intriguingly, 
suppression of viral replication, whether spontaneous or mediated 
by antiretroviral therapy, was associated with more potent effector 
activity, indicating that specific and global inflammatory cues likely 
have a complex role in determining antibody glycosylation.
While alterations in antibody glycosylation are present in 
numerous disease states, we were surprised to find here that (a) 
despite its long plasma half-life, global plasma IgG glycosylation 
was significantly perturbed during acute infection; and (b) anti-
bodies from elite controllers, whose plasma generally does not 
exhibit traditional markers of inflammation, exhibited the most 
profound IgG glycan skewing. The impact of these global glycosy-
lation changes on humoral immunity is unknown. Furthermore, 
we found that glycosylation patterns were different between bulk 
plasma antibody and HIV-specific fractions, indicating that the 
immune system has evolved means to both globally and specifi-
cally, in an antigen-dependent manner, shift antibody function. 
Defining the signals responsible for the modulation of glycosy-
lation in both global and disease-specific antibody repertoires is 
likely to be of great clinical relevance in disease states in which 
antibodies play either protective or pathological roles.
Given the dramatic activity differences in cell-based assays, gly-
can modulation among subject groups was surprisingly small, 
leading to the possible conclusion that subtle glycan modulation 
Figure 5
Antiviral activity is associated with specific glycoforms and FCGR3A binding. (A) Total agalactosylated (G0 class) glycans prevalence correlates 
positively with ADCVI activity. (B) Bigalactosylated (G2 class) glycans prevalence correlates negatively with NK cell ADCVI activity. (C) Bulk 
plasma antibody affinity for FCGR3A, measured as Biacore response units, correlates positively with ADCVI activity. (D) Impact of enzymatic 
treatment with a galactoside on agalactosylated glycan and (E) bigalactosylated glycan content. (F) Binding of treated and untreated antibody 
samples to FCGR3A beads. (A–C and F) Individual symbols represent each subject tested, and horizontal lines represent the median for a given 
group of clinically related subjects.
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may lead to significant activity differences, with minor glycan spe-
cies capable of playing a significant role in overall antibody effec-
tor function. This possibility is consistent with other studies in 
which minor glycan species have been found to be responsible for 
overall antibody activity (29). Alternatively, because the experimen-
tal methods used here could not simultaneously define either the 
subclasses associated with each glycan structure or assign both Fc 
glycans present on a given antibody molecule, it is possible that 
if this level of resolution were possible, perhaps more dramatic 
differences among subject groups would have been apparent. Fur-
thermore, while some generally applicable principles regarding the 
effector function of glycans have been determined in studies of 
monoclonal antibodies, such as the role of fucose in modulating 
ADCC activity, the context in which these saccharides are present 
may be important — with fucose having a greater or lesser effect in 
the context of G0, G1, G2, or bisected glycan chains.
Despite these limitations, a clear association between galactose 
levels and ADCVI activity was observed. This association was 
surprising in that increased galactosylation has tended to drive 
better ADCC in recombinantly produced monoclonal antibodies 
(26). While there are a number of plausible explanations for this 
discrepancy, the simplest is that, in naturally produced antibod-
ies, galactosylation covaries with differential sialylation, as sialic 
acids are incorporated via linkages to terminal galactose groups. 
Recombinant monoclonal antibodies, typically secreted from ani-
mals, and non–B cell types may not exhibit the same covariation 
in galactose and sialylation or may differ in isomerization patterns 
due to inherent differences in GT expression or antibody traffick-
ing and processing in the endoplasmic reticulum. Similarly, covari-
ation of oligomannose intermediates may be a confounding factor 
in studies of recombinant antibodies, whereas these high mannose 
forms known to have improved ADCC activity are extremely rare 
in naturally expressed human antibodies. Alternatively, antibody 
galactosylation has recently been associated with antiinflamma-
tory activity following FcgR ligation via interactions with addi-
tional binding partners (30). However, here we show that beyond 
associated minor glycan species changes, agalactosylated antibod-
ies themselves may have an enhanced capacity to bind to FCGR3A, 
potentially resulting in more potent ADCC/ADCVI activity.
Alterations in antibody glycosylation ultimately result from 
altered glycan biosynthesis on a cellular level, likely due to 
changes in the expression of enzymes involved in N-linked gly-
can biosynthesis or due to the rate of antibody transit through 
the endoplasmic reticulum prior to secretion. HIV infection was 
associated with significant shifts in the expression of several GTs 
and glycosidases, which are involved in multiple steps of glycan 
synthesis, consistent with the production of a larger population 
of agalactosylated antibodies. Moreover, elite controllers exhibit 
an enzyme expression profile marked by changes in enzyme 
expression, likely resulting in the production of a larger fraction 
of nonfucosylated antibodies, suggesting that distinct inflam-
matory cues or differences in the mechanism of B cell priming 
or education may result in the skewed expression of the enzymes 
involved in tuning antibody Fc effector functions. Ultimately, 
understanding the mechanism by which these enzymes are reg-
ulated, particularly in HIV-specific B cells, may provide opportu-
nities to begin to define novel strategies by which vaccines could 
elicit more antiviral innate immune recruiting antibodies.
Overall, we believe these studies highlight the first example of 
skewed glycosylation of disease-specific antibodies in HIV infec-
tion and, more importantly, that these shifts are regulated by 
both general inflammatory cues as well as antigen-specific fine 
adjustments, resulting in the production of antibodies with 
enhanced effector functions. However, whether antibody gly-
cosylation can be regulated permanently in memory B cells or 
long-lived plasma cells provides an exciting prospect for future 
vaccine efforts aimed at potentiating the functional capacity of 
vaccine-induced antibody responses.
Figure 6
Transcriptional profiling of GTs and glycosidases relevant to IgG glycans in peripheral B cells. (A) GTs involved in synthesis of all antibody gly-
cans, the MGAT1 and MGAT2 enzymes involved in the conversion of oligomannose to complex N-glycans and ALG2 involved in initiating N-linked 
glycosylation, were upregulated in untreated subjects. (B) Fucosyltransferase FUT8 expression was increased in untreated progressors, while 
fucosidase FUCA2 was increased in controllers and untreated progressors. (C) Galactose transferases B4GALT1 and B4GALT3 were decreased 
in HIV-infected subjects. The y axis represents transcript expression relative to a housekeeping gene. Individual symbols represent each subject 
tested, and horizontal lines represent the median for a given group of clinically related subjects. *P < 0.05; **P < 0.005; ***P < 0.0005.
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Subjects. A total of 90 subjects, including 10 acute/early HIV-infected indi-
viduals, 24 chronically infected individuals off therapy, 24 chronically 
infected subjects receiving treatment, 22 controllers, and 10 HIV-negative 
individuals, were recruited for antibody analysis studies. The 10 acute/
early HIV-infected subjects, defined as p24-antibody negative or Western 
blot indeterminate, were recruited within the first 5 months of infection 
and were followed longitudinally in the absence of antiretroviral therapy. 
GT expression analysis was conducted on a second group of 61 subjects, 
and subject characteristics for each study group are reported in Supple-
mental Table 1. The local and Massachusetts General Hospital Institu-
tional Review Boards approved the study, and each subject provided writ-
ten informed consent for participation in the study.
Antibody purification. Bulk IgG was purified from 200 μl of plasma using 
a Melon Gel IgG Purification Kit (Thermo Scientific). Briefly, the resin 
was washed twice with Melon Gel buffer and incubated with diluted 
plasma on a rotator for 5 minutes to allow for the binding of plasma pro-
teins. Antibodies were spun through the resin, and the concentration was 
calculated using a Nanodrop spectrophotometer (Thermo Scientific). 
Following IgG purification, HIV-specific antibodies were affinity puri-
fied using a custom amino-link (Pierce) gp120 resin. Each microcolumn 
was conjugated with 100 μg gp120 (Immune Technologies) according 
to the manufacturer’s protocol. Conjugation efficiency was determined 
to be at least 50% for all columns prepared. Each column was used to 
process IgG from a single subject. Briefly, purified subject IgG (2–10 mg) 
was incubated with the resin prior to washing and low pH elution. Eluted 
antibodies were immediately neutralized. Analysis was performed to ver-
ify that brief acid exposure did not alter glycan composition and that 
gp120 was not released from the resin. Antibodies titers were determined 
by ELISA as described previously (21), and enrichment of gp120-specific 
antibodies was confirmed by ELISA.
ADCVI assay. The capacity of plasma antibodies to recruit the antiviral 
activity of NK cells and suppress viral replication was measured using an 
ADCVI assay (20). Briefly, PBMCs from an HIV-1–negative donor were 
cultured with a CD3/8 bispecific antibody (0.3 μg/ml) for 4 days in the 
presence of 50 U/ml IL-2 (NIH) to produce activated CD4+ T cells. On 
the fourth day, the CD4+ T cells were infected at an MOI of 0.01 with an 
R5 viral strain (JRCSF). In parallel, NK cells were purified from the same 
donor using negative selection (RosetteSep; Stem Cell Technologies). 
The purified IgG was added to the CD4+ T cells (10 μg/ml) in duplicate, 
and NK cells were added to one of the duplicate wells. The supernatant 
was collected on day 7, and the level of inhibition was quantified as the 
difference in p24 produced in wells containing antibodies/effectors com-
pared with wells containing CD4+ T and NK cells alone. Each data point 
represents the average of 3 independent experiments using different 
autologous effector/target donors. Supplemental Figure 4 presents the 
reproducibility of this ADCVI assay across multiple donors assessed on 
different days. To reduce inhibition due to NK cells alone, only KIR3DS1– 
donor cells were used (31). A subset of antibody samples were treated 
with PNGaseF (New England Biolabs) to remove N-linked glycans, as 
previously described (32). The presence of inactivated PNGaseF did not 
affect the ADCVI assay results.
Antibody-induced NK cell degranulation assay. Intracellular cytokine stain-
ing was used to determine whether the IgG purified from the plasma of 
acutely infected subjects exhibited a differential capacity to promote NK 
cell cytokine secretion and/or degranulation as a surrogate for NK cell 
cytolysis (19). Briefly, activated CD4+ T cells were prepared as described 
for the ADCVI assay. In parallel, NK cells were purified by negative selec-
tion and cultured in media supplemented with 50 U/ml IL-2 for 4 days. 
On day 4, the CD4+ T cells were infected with a VSV-pseudotyped R5 
virus (JRCSF) for 2 hours and then cultured for an additional 2 days. 
On day 6, CD4+ T cells were then counted and split into duplicate FACS 
tubes. The purified IgG was added at 50 μg/ml to each duplicate tube, 
and NK cells were added to one of the tubes at an effector to target ratio 
of 1:1. Anti-CD107a-PECy5 (20 μl/ml; BD Biosciences), Brefeldin A 
(0.5 μg/ml; Sigma-Aldrich), and Golgi-stop (0.3 μg/ml; BD Biosciences) 
were added, and the tubes were incubated for 6 hours at 37°C. NK cells, 
either alone or in the presence of uninfected CD4+ T cells, were used as a 
negative control, and NK cells stimulated with PMA/ionomycin (1 μg/ml) 
were used as a positive control. Following incubation, the samples were 
stained with anti-CD3-Pacific Blue, anti-CD56-PE-Cy7, and anti-CD16-
APC-Cy7 (BD Biosciences) to define NK cells; fixed; permeabilized (FIX-
A/B, Caltag/Invitrogen); and then stained with anti-IFN-γ-FITC and 
anti-TNF-α-Alexa 700 (BD Biosciences). The cells were then resuspended 
in 100 μl 2% paraformaldehyde-PBS, and data were acquired on a BD 
LSRII. The proportion of degranulated or cytokine-secreting NK cells 
was then calculated as follows: (percentage of cells that were positive 
for the marker of interest / percentage of cells that responded to PMA/
ionomycin) × 100. The background level of NK cell activation by HIV-in-
fected autologous cells was subtracted from the experimental values, and 
a response was considered positive if the proportion of CD107a-express-
ing or cytokine-positive cells following stimulation was at least 2-fold 
greater than the mean of the no plasma controls. Supplemental Figure 
5 presents the correlation of ADCVI assay results presented in this study 
with NK cell degranulation and cytokine secretion.
FcγRIIIa/antibody affinity assays. Surface plasmon resonance was used to 
measure the strength of the antibody-FCGR3A interaction. Wells on a Bia-
core CM5 research-grade chip were coated with 5 μg recombinant FcγRIIIa 
or a control protein (Staphylococcal enterotoxin B, Sigma-Aldrich). Purified 
bulk IgG was diluted to a concentration of 0.2 μg/ml, and the binding 
affinity was calculated as the peak relative units of binding for each anti-
body sample normalized to control protein binding. Binding of the mono-
clonal IgG1 b12 antibody was used as a positive control, and the mutant 
LALA b12 variant (provided by Dennis Burton, The Scripps Research Insti-
tute, La Jolla, California, USA), with impaired FcR binding activity, was 
used as a negative control.
Generation of G0 antibodies. To generate hypogalactosylated antibody, IgG 
(10 ml of 0.250 mg/ml) was isolated from healthy donor plasma using 
protein G beads (GE Healthcare) and incubated overnight at 37°C in 
neuraminidase (500 U/ml, New England Biologicals), as per manufacturer 
instructions. The solution containing desialyated IgG was supplemented 
with NaCl to a final concentration of 100 mM and incubated overnight at 
37°C with β-1,4-galactosidase (20 U/ml, New England Biologicals) 3 times. 
Galactose content was determined by HPLC (33).
FCGR3A binding activity. A customized Luminex assay was developed in 
which recombinant FCGR3A was covalently conjugated to magnetic beads 
and incubated in antibody over a dilution range, and bound antibody was 
quantified with phycoerythrin-conjugated mouse anti-human IgG, in an 
adaptation of a previously described protocol (34). Binding of a series of Fc 
domain amino acid point mutants was used to validate that signal in this 
assay correlated with binding affinity (data not shown).
Glycan analysis by mass spectrometry. Enzymatic release of N-linked glycans 
was performed according to the method of Küster (35). Oligosaccharides 
were released from bands containing approximately 10 μg target glycopro-
tein that was excised from Coomassie blue–stained reducing SDS-PAGE 
gels, washed with alternating water and acetonitrile, and dried in a vacuum 
centrifuge, followed by rehydration with 100 units/ml of PNGase F (New 
England Biolabs) and incubation for 12 hours at 37°C. The enzymatically 
released N-linked glycans were eluted with water. Aqueous solutions of the 
glycans were cleaned with a Nafion 117 membrane.
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of its ability to predict patient class, including a naive Bayes (NB) classi-
fier, linear discriminant analysis (LDA), and a linear-kernel support vec-
tor machine (SVM) approach with a voting mechanism combining binary 
classifiers for multiclass classification. The classifiers were implemented in 
the R programming language (42), using the e1071 package. Classification 
analysis was conducted using a subset of the GTs identified by the Boruta 
algorithm (43) as features relevant to discriminating among these subject 
classes. Features identified as relevant to resolving infected versus unin-
fected subjects were the expressions of B4GALT4, MGAT2, MGAT4A, and 
FUCA2. Features with value in resolving all subject classes included ALG2, 
B4GALT1, B4GALT3, MGAT2, MGAT3, MGAT4A, and FUCA2. The pre-
dictive performance of each classifier was assessed with 100 replicates of 
5-fold cross validation. Each of the 3 methods (NB, LDA, and SVM) gave 
similar performance results.
Statistics. An ANOVA with a post-hoc Tukey’s test was used to test for 
differences in the mean among several populations. Spearman correlations 
were used to examine the interrelatedness of different parameters. P values 
less than 0.05 were considered significant.
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Positive-ion MALDI-TOF mass spectra were recorded with a Shimadzu 
AXIMA TOF2 MALDI-TOF/TOF instrument (Shimadzu-Kratos) fitted with 
delayed extraction and a nitrogen laser (337 nm). The acceleration voltage 
was 20 kV; the pulsed extraction was optimized for m/z 1,700. Samples were 
prepared by adding 0.5 μl of an aqueous solution of the sample to the matrix 
solution (0.3 μl of a saturated solution of 2,5-dihydroxybenzoic acid in aceto-
nitrile) on the stainless steel target plate and allowing it to dry at room tem-
perature. The sample/matrix mixture was then recrystallized from ethanol.
Negative-ion ESI mass spectrometry was performed with a Waters Synapt 
G2 quadrupole-ion mobility-TOF (Q-IMS-TOF) mass spectrometer (Waters 
MS Technologies) for samples with sufficient material remaining. Sample 
were dissolved in 1:1 (v/v) water/methanol (8 μl), 1 μl of a 1 M solution of 
ammonium phosphate was added, and the samples were spun at 3,000 g in 
a bench centrifuge for 1 minute. Sample introduction into the mass spec-
trometer was via Waters thin-wall nanospray capillaries. The ion source tem-
perature was maintained at 120°C, and fragmentation was performed, with 
argon, in the instrument’s transfer cell. The collision energy was adjusted 
according to the mass of the parent ions to give an even distribution of 
fragments across the mass range. Instrument control and data processing 
were performed with Waters MassLynx software, version 4.1. Fragmentation 
spectra were interpreted as described by Harvey et al. (36–39).
GT expression profiling. CD3–CD19+CD27+ cells were separated by mag-
netic separation (Miltenyi Biotec), and the transcriptional profile of these 
peripheral B cells was determined using Illumina HumanHT-12 whole-ge-
nome expression BeadChips. Briefly, following incubation with magnetic 
microbeads, cells were thoroughly washed, and a minimum of 5 × 105 
pure B cells from each subject was resuspended in RNA later. RNA was 
extracted using the Qiagen RNeasy Kit (Qiagen). Then, 200 ng of total 
RNA was amplified using the Ambion Illumina TotalPrep RNA Amplifi-
cation Kit, and 1,500 ng of the amplified cDNA was hybridized overnight 
to the BeadChip. After a series of washes, BeadChips were read using the 
Illumina BeadStation. The resulting images were analyzed using the Illu-
mina BeadStudio software, and internal controls were evaluated for each 
sample to quality control the data. Data from the samples that passed 
chip processing quality control was exported and normalized, and expres-
sion for a set of 16 GTs with possible activities relevant to the antibody 
N-linked glycan, as described by the Korean Encyclopedia of Genes and 
Genomes (KEGG) database (40, 41), was extracted. Data presented rep-
resent expression amplitude (log2).
Subject classification analysis. Three commonly used methods were selected 
to analyze the information content of the GT expression data set in terms 
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